BRF2

Across TCGA pan-cancer cohorts, BRF2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of BRF2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where BRF2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BRF2 is over-expressed in tumor, although a few such as COAD and OV show the opposite, repressed pattern.

LSCC, HNSC, and LUAD are the cancer types where BRF2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRF2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.633	<.001	7	view →
HNSC	All	All	+0.426	.015	3	view →
LUAD	All	All	+0.234	.007	3	view →
COAD	Female	All	−0.740	.001	2	view →
OV	All	All	−0.648	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

BRF2–LSCC

Open the LSCC breakdown →